Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2480–2483. doi: 10.1128/aac.41.11.2480

Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.

D R Van Harken 1, J C Pei 1, J Wagner 1, I M Pike 1
PMCID: PMC164148  PMID: 9371353

Abstract

This nonrandomized, two-period crossover study was performed to assess whether concomitant administration of megestrol acetate influences the steady-state pharmacokinetics of zidovudine and its inactive 5'-O-glucuronide metabolite. Twelve HIV-positive, asymptomatic male volunteers received a 100-mg oral capsule dose of zidovudine at least 30 min before meals five times a day at 0700, 1100, 1500, 1900, and 2300 h on study days 1 to 3 and a single 100-mg dose at 0700 h on day 4. On days 5 to 17, 800 mg of megestrol acetate, as a 40-mg/ml aqueous suspension, was administered orally immediately before the 0700 h dose of zidovudine. On days 5 to 16, zidovudine was also administered at 1100, 1500, 1900, and 2300 h. Serial blood samples were collected for 12 h after the single 100-mg dose of zidovudine on days 4 and 17; trough samples were also obtained just before the 0700 h dose on days 2 to 4 and 15 to 17. Levels of zidovudine and its glucuronide in plasma were assayed by a validated radioimmunoassay. Statistical analysis of trough plasma level data indicated that steady-state levels of zidovudine and its glucuronide in plasma had been attained when pharmacokinetic assessments were made on days 4 and 17. When megestrol acetate and zidovudine were coadministered for 13 days, differences of -14, -6.5, and -4.6% in mean zidovudine peak concentration and areas under the curve at 0 to 4 and 0 to 12 h, respectively, +22.5% in mean trough concentration, +2.6% in mean plasma half-life, and no change in median time to peak were observed compared to conditions when zidovudine was administered alone; for zidovudine 5'-O-glucuronide the respective differences were -9, -7.3, -4.4, +2.3, and +10% and no change. None of the differences were statistically significant (P > 0.05). Concomitant therapy with megestrol acetate, at the dose employed to treat anorexia, cachexia, or an unexplained, significant weight loss in AIDS patients, did not alter the steady-state pharmacokinetics of zidovudine or its 5'-O-glucuronide metabolite.

Full Text

The Full Text of this article is available as a PDF (169.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aweeka F. T., Gambertoglio J. G., van der Horst C., Raasch R., Jacobson M. A. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob Agents Chemother. 1992 Aug;36(8):1773–1778. doi: 10.1128/aac.36.8.1773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burger D. M., Meenhorst P. L., Koks C. H., Beijnen J. H. Drug interactions with zidovudine. AIDS. 1993 Apr;7(4):445–460. doi: 10.1097/00002030-199304000-00001. [DOI] [PubMed] [Google Scholar]
  3. Burger D. M., Meenhorst P. L., Koks C. H., Beijnen J. H. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993 Jul;37(7):1426–1431. doi: 10.1128/aac.37.7.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burger D. M., Meenhorst P. L., Underberg W. J., van der Heijde J. F., Koks C. H., Beijnen J. H. Short-term, combined use of paracetamol and zidovudine does not alter the pharmacokinetics of either drug. Neth J Med. 1994 May;44(5):161–165. doi: 10.1016/0300-2977(95)90002-0. [DOI] [PubMed] [Google Scholar]
  5. Chatton J. Y., Munafo A., Chave J. P., Steinhäuslin F., Roch-Ramel F., Glauser M. P., Biollaz J. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol. 1992 Dec;34(6):551–554. [PMC free article] [PubMed] [Google Scholar]
  6. Cooper J. M., Kellie A. E. The metabolism of megestrol acetate (17-alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione) in women. Steroids. 1968 Feb;11(2):133–149. doi: 10.1016/0039-128x(68)90004-4. [DOI] [PubMed] [Google Scholar]
  7. Dudley M. N. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis. 1995 Mar;171 (Suppl 2):S99–112. doi: 10.1093/infdis/171.supplement_2.s99. [DOI] [PubMed] [Google Scholar]
  8. Gibb D., Barry M., Ormesher S., Nokes L., Seefried M., Giaquinto C., Back D. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. Br J Clin Pharmacol. 1995 May;39(5):527–530. doi: 10.1111/j.1365-2125.1995.tb04490.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gitterman S. R., Drusano G. L., Egorin M. J., Standiford H. C. Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther. 1990 Aug;48(2):161–167. doi: 10.1038/clpt.1990.131. [DOI] [PubMed] [Google Scholar]
  10. Hendrix C. W., Flexner C., Szebeni J., Kuwahara S., Pennypacker S., Weinstein J. N., Lietman P. S. Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1994 May;38(5):1036–1040. doi: 10.1128/aac.38.5.1036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
  12. Kornhauser D. M., Petty B. G., Hendrix C. W., Woods A. S., Nerhood L. J., Bartlett J. G., Lietman P. S. Probenecid and zidovudine metabolism. Lancet. 1989 Aug 26;2(8661):473–475. doi: 10.1016/s0140-6736(89)92087-4. [DOI] [PubMed] [Google Scholar]
  13. Lee B. L., Täuber M. G., Sadler B., Goldstein D., Chambers H. F. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther. 1996 Jan;59(1):14–21. doi: 10.1016/S0009-9236(96)90019-3. [DOI] [PubMed] [Google Scholar]
  14. Lertora J. J., Rege A. B., Greenspan D. L., Akula S., George W. J., Hyslop N. E., Jr, Agrawal K. C. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1994 Sep;56(3):272–278. doi: 10.1038/clpt.1994.137. [DOI] [PubMed] [Google Scholar]
  15. Mole L., Israelski D., Bubp J., O'Hanley P., Merigan T., Blaschke T. Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. J Acquir Immune Defic Syndr. 1993 Jan;6(1):56–60. [PubMed] [Google Scholar]
  16. Morse G. D., Portmore A., Olson J., Taylor C., Plank C., Reichman R. C. Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1990 Mar;34(3):394–397. doi: 10.1128/aac.34.3.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Morse G. D., Shelton M. J., Ho M., Bartos L., DeRemer M., Ragni M. Pharmacokinetics of zidovudine and didanosine during combination therapy. Antiviral Res. 1995 Aug;27(4):419–424. doi: 10.1016/0166-3542(95)00032-h. [DOI] [PubMed] [Google Scholar]
  18. Morse G. D., Shelton M. J., O'Donnell A. M. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet. 1993 Feb;24(2):101–123. doi: 10.2165/00003088-199324020-00002. [DOI] [PubMed] [Google Scholar]
  19. Mueller B. U., Pizzo P. A., Farley M., Husson R. N., Goldsmith J., Kovacs A., Woods L., Ono J., Church J. A., Brouwers P. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr. 1994 Jul;125(1):142–146. doi: 10.1016/s0022-3476(94)70141-5. [DOI] [PubMed] [Google Scholar]
  20. Nokta M., Loh J. P., Douidar S. M., Ahmed A. E., Pollard R. B. Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. J Interferon Res. 1991 Jun;11(3):159–164. doi: 10.1089/jir.1991.11.159. [DOI] [PubMed] [Google Scholar]
  21. Oster M. H., Enders S. R., Samuels S. J., Cone L. A., Hooton T. M., Browder H. P., Flynn N. M. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994 Sep 15;121(6):400–408. doi: 10.7326/0003-4819-121-6-199409150-00002. [DOI] [PubMed] [Google Scholar]
  22. Qian M. X., Swagler A. R., Mehta M., Vishwanathan C. T., Gallo J. M. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. Pharm Res. 1992 Feb;9(2):224–227. doi: 10.1023/a:1018941507979. [DOI] [PubMed] [Google Scholar]
  23. Sahai J., Gallicano K., Garber G., Pakuts A., Cameron W. Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):54–60. [PubMed] [Google Scholar]
  24. Sahai J., Gallicano K., Garber G., Pakuts A., Hawley-Foss N., Huang L., McGilveray I., Cameron D. W. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1992 Nov;52(5):464–470. doi: 10.1038/clpt.1992.173. [DOI] [PubMed] [Google Scholar]
  25. Sahai J., Gallicano K., Pakuts A., Cameron D. W. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis. 1994 May;169(5):1103–1107. doi: 10.1093/infdis/169.5.1103. [DOI] [PubMed] [Google Scholar]
  26. Von Roenn J. H., Armstrong D., Kotler D. P., Cohn D. L., Klimas N. G., Tchekmedyian N. S., Cone L., Brennan P. J., Weitzman S. A. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994 Sep 15;121(6):393–399. doi: 10.7326/0003-4819-121-6-199409150-00001. [DOI] [PubMed] [Google Scholar]
  27. Wilde M. I., Langtry H. D. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993 Sep;46(3):515–578. doi: 10.2165/00003495-199346030-00010. [DOI] [PubMed] [Google Scholar]
  28. de Miranda P., Good S. S., Yarchoan R., Thomas R. V., Blum M. R., Myers C. E., Broder S. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther. 1989 Nov;46(5):494–500. doi: 10.1038/clpt.1989.176. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES